What is NanoDx?
NanoDx is a pioneering healthcare technology company dedicated to enhancing global well-being by developing innovative solutions powered by its proprietary nano biosensor platform. The company's technology is designed to create a healthier, safer, and happier world by providing advanced diagnostic and monitoring capabilities. With a focus on leveraging cutting-edge nanotechnology, NanoDx aims to address critical healthcare challenges and improve patient outcomes worldwide.
How much funding has NanoDx raised?
NanoDx has raised a total of $30.5M across 7 funding rounds:
Series A
$4M
Private Equity
$1.6M
Series B
$4M
Private Equity
$2M
Private Equity
$557K
Debt
$350K
Series C
$18M
Series A (2013): $4M, investors not publicly disclosed
Private Equity (2014): $1.6M, investors not publicly disclosed
Series B (2016): $4M supported by Provident Healthcare Capital
Private Equity (2017): $2M featuring MedScience Ventures, LLC and Provident Healthcare Capital
Private Equity (2017): $557K, investors not publicly disclosed
Debt (2020): $350K with participation from PPP
Series C (2020): $18M led by Shepherd Kaplan Krochuk, LLC
Key Investors in NanoDx
Provident Healthcare Capital
Provident Healthcare Capital is a specialized investment banking firm focused on the healthcare sector, providing M&A, financing, and advisory services to private healthcare companies. They leverage extensive industry expertise to achieve optimal transaction outcomes for their clients.
MedScience Ventures, LLC
MedScience Ventures, LLC is an investment firm dedicated to fostering innovation within the life sciences sector through strategic investments and collaborations. They aim to bridge life sciences and culture, supporting advancements in the industry.
Shepherd Kaplan Krochuk, LLC
Shepherd Kaplan Krochuk, LLC is an entity that has participated in NanoDx's funding rounds. Further details on their specific investment focus are not readily available.
What's next for NanoDx?
The recent major strategic investment signals a pivotal phase for NanoDx, likely enabling the company to scale its operations, expand its research and development initiatives, and further commercialize its nano biosensor technology. This infusion of capital is anticipated to fuel the company's expansion into new markets and solidify its competitive advantage. The strategic nature of the investment suggests potential collaborations or partnerships that could enhance NanoDx's market penetration and technological advancements, positioning it for sustained growth and leadership in the healthcare innovation landscape.
See full NanoDx company page
